Clinical Trials Logo

Severe Hypertriglyceridemia clinical trials

View clinical trials related to Severe Hypertriglyceridemia.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06347016 Recruiting - Clinical trials for Severe Hypertriglyceridemia

Study of Plozasiran in Adults With Severe Hypertriglyceridemia

SHASTA-4
Start date: May 2024
Phase: Phase 3
Study type: Interventional

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After Month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol.

NCT ID: NCT06347003 Recruiting - Clinical trials for Severe Hypertriglyceridemia

Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

SHASTA-3
Start date: May 2024
Phase: Phase 3
Study type: Interventional

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol.

NCT ID: NCT05852431 Recruiting - Clinical trials for Severe Hypertriglyceridemia

To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia

ENTRUST
Start date: June 15, 2023
Phase: Phase 3
Study type: Interventional

To determine the effect of Pegozafermin on fasting serum triglyceride levels in subjects with Severe Hypertriglyceridemia (TG ≥500 to ≤2000 mg/dL) after 26 weeks of treatment.

NCT ID: NCT05681351 Recruiting - Clinical trials for Severe Hypertriglyceridemia

A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

Start date: December 13, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.

NCT ID: NCT05552326 Recruiting - Clinical trials for Severe Hypertriglyceridemia

A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia

Start date: August 31, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.

NCT ID: NCT05079919 Recruiting - Clinical trials for Severe Hypertriglyceridemia

A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia

Start date: October 25, 2021
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.